Sanofi calls it quits on mR­NA Covid-19 shots, scrap­ping vac­cine from $3.2B Trans­late Bio buy­out

Sanofi is throw­ing in the tow­el on mR­NA-based Covid-19 vac­cines.

The French drug­mak­er will halt de­vel­op­ment on its un­mod­i­fied mR­NA Covid-19 shot de­spite what it said were pos­i­tive Phase I/II re­sults, a spokesper­son told End­points News on Tues­day morn­ing. Sanofi said the rea­son it’s stop­ping the Covid-19 mR­NA pro­gram, de­vel­oped in part­ner­ship with its new $3.2 bil­lion ac­qui­si­tion Trans­late Bio, is be­cause the mar­ket is too crowd­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER